chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a registered nurse referring to a 65 year old female patient with diabetes, hypertension, hypothyroidism, thrombocytopenia with vitamin B12 deficiency. ON an unknown date the patient was vaccinated with a dose of PNEUMOVAX23 (lot # H021941, expiration date 11-JUL-2014) 0.5 ml, subcutaneous. Concomitant therapies included ASAFEX, lisinopril (manufacturer unknown), metoprolol succinate, aspirin, iron, vitamin C, levothyroxine sodium (manufacturer unknown), JANUMET, CYCLOSET, RESTASIS and vitamin B12. The nurse reported that after receiving a dose of PNEUMOVAX23 on 27-SEP-2013, the patient developed redness, warmth, throbbing and swelling at the injection site, tenderness with arm movement and a low grade fever. The patient was administered a first dose of PNEUMOVAX23 on an unspecified date in the past. The patient went to physicians office and was treated with ibuprofen (manufacturer unknown) and moist heat to injection site. The nurse reported that the patient has improved since 27-SEP-2013 and the patient was instructed to continue using ibuprofen (manufacturer unknown) and moist heat. Additional information is not expected.
Note:  Shot was administered at Clinic . not Dr. office.  Beginning on the evening of 1/29/21 I began experiencing Chills, a slight fever of 100.3 and extreme fatigue. These conditions continued for a period of 3 days.  At that point I also began to experience shortness of breath and my O2 level dropped to 78%.  I began using a nebulizer, spirometer,  flutter valve and exercises at that point and over the next several days.  Please note that I am a COPD patient and had completed a 16 day course of Prednisone on 1/25/21.  On approximately 2/6/21 my breathing and O2 levels began to return towards normal, although even today I'm still not quite back to what's normal for me.  I am continuing to use the nebulizer, spirometer and flutter value in preparation for shot #2 scheduled for 2/18/21.
65 x 70mm redness and induration at site of injections with small lump under top injection (DTaP) site. Mother noticed afternoon of following day past injection. No fever. No problems walking. Warm compresses.
Patient fully vaccinated (Janssen) but not boosted, admitted to the hospital on 1/19/22 with COVID-19 and associated hypoxia. Patient was discharged on 1/20/22.
Swollen lymph nodes right arm pit Elevated heart rate  dizzy Sweating Unsteady
Post vax, the pt developed redness and induration where the vaccination was given. Resolved as of 11/13/00.
This spontaneous case, initially received from other health professional (nurse) on 19-Oct-2018, concerns a 60-year-old, adult female patient. The patient had no relevant medical history. The patient was not taking any medication at the time of vaccination. On 19-Oct-2018, the patient was administered expired FLUCELVAX QIVc [dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 195250 and expiry date: 30-Jun-2018). At the time of this report, no adverse events were reported. The reporter assessed this case as non-serious. Non-significant follow up received from other health professional on 03-Nov-2018: The reporter confirmed that the patient did not experience any adverse effects after vaccination. No changes were done in the narrative.
on 3rd day p/vax pt devel rash on both legs-papular w/white border-not itchy lasted 3 days;
Starting about 6 hours after getting the vaccine the patient noticed that she couldn't raise her elbow above her shoulder without pain. Then it swelled from her shoulder down to her elbow, became red, and felt really hot. The discomfort and swelling lasted about a day and a half and then started going down. Overall patient noticed it for about 3 days after.
He was diagnosed with intussusception 2/2/08 with respiratory failure. Intussusception relieved via air contrast and reduction. 3/14/08-DC summary received for DOS 2/2/08- 2/5/08-DX Inutssusception. Afternoon of admission became fussy, refused to eat and developed pale lips. Intubated.  Respiratory failure secondary to intussusception. Extubated with stridor improved to room air.
less intense itching; milder reaction- painful; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE PRURITUS and VACCINATION SITE PAIN in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 029K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021 at 2:15 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Feb-2021, the patient experienced VACCINATION SITE PRURITUS and VACCINATION SITE PAIN. At the time of the report, VACCINATION SITE PRURITUS and VACCINATION SITE PAIN outcome was unknown.            Concomitants include air Shield Immunity Support Gummies once daily start date 03-01-2021. Treatment include hydrocortisone cream.  Action taken with mRNA-1273 in response to the event was not applicable.    This case was linked to MOD-2021-025504.
Child had swelling on Right leg (knee to thigh). Mother advised to take to PCP. PCP told mother swelling appears to be muscle swelling from immunization. No treatment.
The pain I feel, Could be due to a blood clot?; pain on my arm; felt numbness in my arm; now I feel it on the inside, like if it was in the bone.; This is a spontaneous report from a contactable consumer (patient). A 42-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration in the arm on an unspecified date (Batch/Lot number was not reported) as a single dose for COVID-19 immunization. Medical history was not reported. Concomitant medication included paracetamol (TYLENOL) taken for an unspecified indication, start and stop date were not reported. The patient received the Pfizer Covid 19 vaccine on Friday, since then she felt pain on her arm, it got stronger in the afternoon, she couldn't lift anything or move that arm. On Saturday, the pain diminished. On the day of the report, the patient still feel pain, but now is like an internal ache, like if it is in the bone. She had trouble getting dressed, specially putting on t-shirts, when she goes to sleep, she cannot lay on that arm. It was reportedly very painful, and she was feeling as if it has moved to the other arm. On the day of the report, she applied heat on her arm and took Tylenol on Friday and Saturday. On Friday, she couldn't do anything, she felt numbness in her arm. Initially the pain was external, now she feels it on the inside, like if it was in the bone. The patient also asked if the pain she feel could be due to a blood clot. The event pain on my arm resolved on an unknown date in 2021, while the outcome of the rest of the events was unknown.   Information about lot/batch number has been requested.
This case involves a 64 year old male patient who experienced itchiness and rash while receiving vaccine INFLUENZA VACCINE. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination. On an unknown date the patient developed a non-serious event "itchiness"? (pruritus) (unknown latency) following the administration of INFLUENZA VACCINE. On an unknown date the patient developed a non-serious event "rash" (unknown latency) following the administration of INFLUENZA VACCINE. It was reported, "Caller states she has a 64 year old patient that had a previous reaction to a flu shot a few years back and the patient developed a rash and some itchiness afterwards. Caller did state that the patient received FLUBLOK afterwards with no reaction or issues. Caller does not believe the patient has an egg allergy since he does eat egg products, and believes he may have had a reaction to the preservative in the original vaccine." Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable. It was not reported if the patient received a corrective treatment for the events (itchiness, rash). At time of reporting, the outcome was Recovered / Resolved on an unknown date for the event itchiness and was Recovered / Resolved on an unknown date for the event rash.
Patient received the Moderna COVID 19 vaccine after temperature excursion; Patient received the Moderna COVID 19 vaccine after temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patient received the Moderna COVID 19 vaccine after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient received the Moderna COVID 19 vaccine after temperature excursion) in a 19-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 23-May-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 23-May-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patient received the Moderna COVID 19 vaccine after temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patient received the Moderna COVID 19 vaccine after temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patient received the Moderna COVID 19 vaccine after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient received the Moderna COVID 19 vaccine after temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The reporter stated that, in her facility where she works at there has been temperature excursions with her freezer. It has been happening for weeks since April 2022.   The storage condition at the time of the excursion was frozen. The vial with lot number affected were 065K21A and 045L21A. The maximum or minimum temperatures reached were as follows maximum: 30 Fahrenheit Degrees and minimum -18.9 Fahrenheit Degrees. The vaccines suffered 2 temperature excursions since April, both lasted less than 1 minute. The reporter does not have the information on date vial(s) moved from freezer to refrigerator. The vials currently stored in frozen state. On visual inspection no changes were observed in any vaccine state. The Proposed desired Use by Date was not reported.  No treatment medications were reported.   This case was linked to MOD-2022-591989 (Patient Link).
10/4/11 Received Flu shot. 10/5/11 Sharp pain in back. 10/20/11 Experienced severe leg pain. Walked with walker. 10.25/11 Went to emergency room because my leg would not work and had extreme pain. Came home. Went to clinic. Noted foot drop. Had MRI of Lumbar same day. On 11/3/11 saw neurosurgeon. He referred me to neurologist. Had nerve conduction test on 11/7/11/. Dr. diagnosed GBS. Immediately went to hospital (from 11/7 - 11/15/11 in hospital. Lumbar puncture confirmed GBS. Treated 5 doses IVIG 11/30 - 12/5/11. Back in hospital. Still in PT. Continue with adverse effects.
This spontaneous report as received from a healthcare worker refers to several patients of unknown age and gender. The healthcare worker reported that several patients have been administered with a dose of GARDASIL, ROTATEQ, RECOMBIVAX HB and VARIVAX (Merck) (lot# and expiry unknown) between 04-MAR-2014 and 06-MAR-2014 which were exposed to temperatures outside the prescribing information although supported. No adverse effects reported. The case is linked to 1403USA008918, 1403USA008919 and 1403USA005434 (same reporter link). Additional information has been requested.
Patient received Pfizer vaccine as dose 2 in series in place of Moderna [Dose #1 received 6/1/2021]
Pt recvd vax 9SEP92 pt fussy 10SEP & 11SEP; fever to 39.4 11SEP; found staring, pale, lethargic 12SEP @ approx 1AM; MD evaluated the pt & adm to hosp;
Redness, warmth and swelling to (L) thigh. BENADRYL OTC and Orapred x 3days.
Chest Pain, shortnes of Bread, Rash all over the body, swollen on face. Had happen multiple times and still happen. Eveytime is worst.
Rash developed next day. Rash spread from arm to rest of body.; Lightheaded and dizziness.; Lightheaded and dizziness.; This is a spontaneous report from a contactable healthcare professional. A 51-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via intramuscular route of administration in the left arm on 06Apr2021 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, depression, hypercholesteremia. The patient previously took penicillin and experienced penicillin allergy. The patient previously took Bactrim and Levaquin and experienced drug allergy to Bactrim and Levaquin. Concomitant medications taken within two weeks of vaccination included atorvastatin (MANUFACTURER UNKNOWN), nebivolol hydrochloride (BYSTOLIC), bupropion (MANUFACTURER UNKNOWN), paracetamol (ACETAMINOPHEN) and loratadine (CLARITIN) all from unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via intramuscular route of administration in the left arm on 18Mar2021 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, the patient experienced lightheaded and dizziness. Rash developed next day on 07Apr2021. Rash spread from arm to rest of body. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of lightheaded, dizziness and rash and included treatment with Hydroxyzine. The clinical outcome of the events lightheaded and dizziness, rash developed next day and rash spread from arm to rest of body was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Vaccine was thawed more than 30 days; Vaccine received post its 30 days Expiry date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine received post its 30 days Expiry date) and PRODUCT STORAGE ERROR (Vaccine was thawed more than 30 days ) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Feb-2022 at 6:43 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 22-Feb-2022 at 6:43 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine received post its 30 days Expiry date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was thawed more than 30 days ). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine received post its 30 days Expiry date) and PRODUCT STORAGE ERROR (Vaccine was thawed more than 30 days ) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported  No treatment medications were reported  It was reported that vaccines were went into thaw state at 2-8 degree on 20-Dec-2021.
Patient states she had joint pain, upper extremity rash, and swelling near injection site, blood pressure elevated since injection, patient stressed out as a result.
Woke up with like the flu; Just sick, with body very sensitive to temperatures; Dont have the energy to do anything; Body aches; The arm  hurt worst that the first one; Was hard to move the arm; A spontaneous report, was received from a consumer (patient), a 69 years-old female patient, unknown race and ethnicity, who was administered Moderna's COVID-19 vaccine (mRNA-1273), and experienced the arm hurt worst that the first one (pain in extremity), was hard to move the arm (hypokinesia), woke up with like the flu (influenza like illness), body aches (pain), just sick, with the body very sensitive to temperatures (feeling hot), and don't have the energy to do anything (asthenia).  The patient's medical history was not provided. The relevant concomitant medications included blood pressure medication.  On 03 Mar 2021, prior to the onset of events, the patient received the second of two planned doses of mRNA-1273 (lot: 010A21A), intramuscularly for the prophylaxis of COVID-19 infection.  On 03 Mar 2021, the patient reported feeling really horrible after the second dose. On the same day, after receiving the vaccine, the patient's arm was hurting worst that the first one and, in the evening, it was hard to move the arm. On 04 Mar 2021, the patient reported that she woke up with flu from thirty years ago and felt like a horrible flu, very bad, with body aches. The patient stated that it was just sick, with the body very sensitive to temperatures. The patient reported that she started to feel a little tiny bit better now but do not have the energy to do anything. The treatment medication included two ibuprofen on the night and two more on the morning.  Action taken with second dose of mRNA-1273 in response to the events was not applicable.  The outcome of the events, arm hurt worst that the first one, was hard to move the arm, woke up with like the flu, body aches, just sick, with the body very sensitive to temperatures, and don't have the energy to do anything were considered as recovering.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
shingles; Information has been received from an attorney regarding a case in litigation. This case refers to a female patient of unknown age. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided. In 2013, the patient received a dose of Zoster Vaccine Live (ZOSTAVAX), (dosage, route, anatomical location, lot number and expiration date were not provided), for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster) at the physician's office. Shortly after receiving the vaccine, the patient was treated by a healthcare professional for shingles. As a direct and proximate result of patient's vaccination, the patient had and would continue to suffer ongoing injuries but not limited to medical and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring treatment, medications and supplies. At the time of the report, the patient had not recovered from the event. The reporter considered the event of shingles to be related to Zoster Vaccine Live (ZOSTAVAX).
Shortness of breathe and throat swelling.  One dose of Epi pen administered and paramedics came and vitals were good. Taken to hospital for observation.
After the second dose has findings of neutropenia; This is a spontaneous report from a Pfizer Sponsored Program via a contactable consumer reported for a patient. A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: unknown, Expiration date: unknown) via an unspecified route of administration, administered at an unspecified anatomical location on an unspecified date (age at vaccination was unknown) as 2nd dose, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: unknown, Expiration date: unknown) via an unspecified route of administration, administered at an unspecified anatomical location on an unspecified date (age at vaccination was unknown) as 1st dose, single for COVID-19 immunization and had no reaction. The reporter was enquiring about the side effect of the COVID vaccine. On an unspecified date, after the second dose the patient had findings of neutropenia and they were trying to figure it out if it would be a side effect. The reporter stated that they were just investigating neutropenia in a patient that had developed recently and they wondered if they had reports of neutropenia in the Pfizer vaccine. The reporter stated that they were not sure if that's what causing in first place they just wanted to know if there had been any report about it. The reporter confirmed Pfizer Covid-19 vaccine. The reporter was informed about the role of Pfizer drug safety and medical information department. The outcome of the event was unknown.   Information on the lot/batch number has been requested. Follow-up attempts not completed; information about lot/batch number cannot be obtained. No further information expected.
devel h/a & vomiting w/in 3hr p/vax;taken by amb to ER;had high fever adm overnoc tx w/IV fluids etc;
This spontaneous report was received from a nurse practitioner regarding 2 unspecified patients of unknown demographics. There was no information regarding concurrent condition and historical medication. On an unknown date the patients were vaccinated with improperly stored ZOSTAVAX, lot # L011528, expiration date- 03-APR-2017. No adverse event was reported. No concomitant medication was reported. The outcome of the event was unknown. Time was 1 hour, temperature 34.7F and there was no previous excursion. This is one of several reports received from the same reporter. Additional information has been requested.
jaw pain; This is a spontaneous report from a contactable consumer (patient). A 69-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number and expiration date was not reported) via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced jaw pain on an unspecified date. It was reported that, she also had jaw pain when she took a Merck product before. She wanted to know if there were reported case for jaw pain and if the pain would be worst after the 2nd dose. Patient took Advil to manage the pain in her jaw and was asking if it was ok. The outcome of the event was unknown.  Information about lot/Batch number has been requested.  Follow-up attempts are completed. No further information is expected.
Developed 4cmX6cm swollen, tender, red, warm area at site of vaccination.